# US 10,501,499 B2 · Peptides derived from viral proteins for use as immunogens and dosage reactants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,499 B2
- Document ID: US10501499B2
- Status: Granted
- Kind: B2
- Application number: 14/406,016
- Filed: 2013-06-06
- Published: 2015-06-04
- Granted: 2019-12-10
- Earliest claimed: 2012-06-06
- Assignees: Bionor Immuno AS
- Applicants: Bionor Immuno AS
- Inventors: Birger Sorensen; Mats Okvist; Arnt Ove Hovden; Maja Sommerfelt Gronvold
- Web page: https://patentgrep.com/patent/US10501499B2

## CPC

- C07K 14/005: from viruses
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- G01N 33/56977: {HLA or MHC typing}
- G01N 2333/045: Cytomegalovirus
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2333/186: Hepatitis C; Hepatitis NANB
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to novel peptides and methods for treatment, diagnosis and prognosis of virus infections including infections with HCV, HIV, HPV, CMV and Influenza. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.

## Claims

### Claim 1

An isolated monomeric peptide comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid, and Glutamic acid, or a derivative thereof; Z3 selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, wherein Nle is Norleucine and Har is homoarginine.

### Claim 2

An isolated dimeric or multimeric peptide comprising two or more covalently joined monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(NLE)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, wherein Nle is Norleucine and Har is homoarginine.

### Claim 3 (depends on 2)

The isolated dimeric or multimeric peptide according to claim 2, wherein two or more monomeric peptides are different in sequence.

### Claim 4 (depends on 1)

A composition comprising two or more compounds selected from a monomeric peptide is as defined in claim 1, and an isolated dimeric or multimeric peptide comprising two or more covalently joined monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRVD (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, wherein Nle is Norleucine and Har is homoarginine.

### Claim 5 (depends on 1)

An immunogenic composition comprising
at least one monomeric peptide according to claim 1, and
an isolated dimeric or multimeric peptide comprising two or more covalently joined monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, wherein Nle is Norleucine and Har is homoarginine.

### Claim 6 (depends on 5)

The immunogenic composition according to claim 5 in the form of a vaccine composition.

### Claim 7 (depends on 1)

A method for inducing an immune response in a subject against an antigen which comprises administration of
at least one monomeric peptide according to claim 1,
an isolated dimeric or multimeric peptide comprising two or more covalently joined monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid, and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, wherein Nle is Norleucine and Har is homoarginine,
a peptide composition comprising two or more compounds selected from a monomeric peptide is as defined in claim 1, and an isolated dimeric or multimericpeptide comprising two or more monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid, and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, wherein Nle is Norleucine and Har is homoarginine.

### Claim 8 (depends on 1)

A peptide according to claim 1, a peptide composition comprising two or more compounds selected from a monomeric peptide is as defined in claim 1, and an isolated dimeric or multimeric dimeric peptide comprising two or more covalently joined monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGAS(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, for use as a medicament, wherein Nle is Norleucine and Har is homoarginine.

### Claim 9 (depends on 1)

A peptide according to claim 1, a peptide composition comprising two or more compounds selected from a monomeric peptide is as defined in claim 1, and an isolated dimeric or multimeric peptide comprising two or more covalently joined monomeric peptides, each monomeric peptide independently comprising the following structure
Z1-Z2-Z3-Z4-Z6-Z7-Z9
wherein Z1, Z4, and optional Z7 defines a linear sequence of one, two, or three arginine residues or derivatives thereof optionally followed by a glycine (G); Z2 defines an optional amino acid selected from 2,3-Diaminopropionic acid (Dpr), Cysteine, Lysine, Aspartic acid and Glutamic acid, or a derivative thereof; wherein Z3 is selected from the group consisting of GGQLIGGIYLIPG (SEQ ID NO:313), VITYSIFLIVS (SEQ ID NO:314), TANWARVIS (SEQ ID NO:315), GYLPAVGAPI (SEQ ID NO:316), NIVP(Nle)VVTA (SEQ ID NO:317), VTPADLIGA (SEQ ID NO:318), PRPEGYTLFF (SEQ ID NO:319), LPYPRGYTLFV (SEQ ID NO:320), ETILTPRDV (SEQ ID NO:321), SSTSPVYDL (SEQ ID NO:322), TAYER(Nle)CNIL (SEQ ID NO:323), TVIGA(Nle)IPLL (SEQ ID NO:324), AAFEE(Nle)(Har)ITS (SEQ ID NO:325), GLEPLVIAGILA (SEQ ID NO:326), TAFLVRNVA (SEQ ID NO:327), TPI(Har)QDWGNRAN (SEQ ID NO:328), TPT(Har)NGWDVKLS (SEQ ID NO:329), LECVYCKQQLL (SEQ ID NO:330), GVYDFAFRDLC (SEQ ID NO:331), GVFDYAFRDIN (SEQ ID NO:332), and VDIRTLEDLL (SEQ ID NO:333); wherein Z6 is selected from the group consisting of EVYDFAFRDLC (SEQ ID NO:334), GFAFRDLCIVY (SEQ ID NO:335), GFAYRDINLAY (SEQ ID NO:336), GTLGIVCPIG (SEQ ID NO:337), GLEPLVIAGILA (SEQ ID NO:338), TPI(Har)QDWENRAN (SEQ ID NO:339), VAFEDL(Har)(Nle)(Nle)SFI (SEQ ID NO:340), RFQTVVQBA (SEQ ID NO:341), GSLVGLLHIVL (SEQ ID NO:342), SIARSVTI(Nle)(Har)ASVVH (SEQ ID NO:343), TPTRQEWDCRIS (SEQ ID NO:344), TPTRQEWDARIS (SEQ ID NO:345), TPI(Har)QEW(Har)SL(Nle)NQEW (SEQ ID NO:346), IGDLIVAQV (SEQ ID NO:347), QYNPVAV(Nle)F (SEQ ID NO:348), GYTLFFTS (SEQ ID NO:349), GYTLFVSD (SEQ ID NO:350), NTL(Nle)TPRDV (SEQ ID NO:351), SSTSPVYNL (SEQ ID NO:352), VITFSIYLIVS (SEQ ID NO:353), GGNVIGGIY(Nle)IPR (SEQ ID NO:354), ANWAKVIL (SEQ ID NO:355), VIRVIAHGLRL (SEQ ID NO:356), and IGDLIVQAV (SEQ ID NO:478); and wherein optional Z9 is NWAKVI, for treating the pathological effects of a disease antigen wherein Nle is Norleucine, and Har is homoarginine.